Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
==== Activity-based Profiling ==== To achieve functional degradomics, the enzymatic activity of proteases must be analyzed. Methods have been developed to distinguish the proteolytic activity of different enzymes in biological samples and separate active proteases from their inactive forms, namely zymogen precursors and those proteases bound by inhibitors. Two techniques are activity-based probes (ABPs) and Proteolytic Signature Peptides (PSPs). ABP molecules serve as probes to irreversibly bind only to active proteases and ignore their zymogen precursors and inhibited proteases. Placing a reactive group and a recognizable tag feature on the same molecule using a linker moiety gives an ABP molecule its structure. The reactive molecule, designed after protease inhibitor mechanisms, lends ABPs their specificity towards targeting active proteases. Once bound, the reactive group acts much like an irreversible inhibitor to the protease. Depending on the nature of the tag moiety, the ABP-protease complex can then be visualized or retrieved from biological samples for further studies of localization and quantification. Limitations including difficult production, specificity, stability, and toxicity hamper ABP development but these probes have proved useful in revealing protease biological activity and remain a promising avenue in degradomic technology. PSPs do not depend on targeting active proteases with tagged compounds but rather on quantitative proteomics using stable isotope labeled standard peptides.
Expectations diminished as a result of numerous failed replications, the retraction of several previously reported positive replications, and the identification of methodological flaws and experimental errors in the original study. By late 1989, most scientists considered cold fusion claims dead, and cold fusion subsequently gained a reputation as pathological science. In 1989 the United States Department of Energy (DOE) concluded that the reported results of excess heat did not present convincing evidence of a useful source of energy and decided against allocating funding specifically for cold fusion. A second DOE review in 2004, which looked at new research, reached similar conclusions and did not result in DOE funding of cold fusion. Presently, since articles about cold fusion are rarely published in peer-reviewed mainstream scientific journals, they do not attract the level of scrutiny expected for mainstream scientific publications. Some interest in cold fusion has continued through the decades—for example, a Google-funded failed replication attempt was published in a 2019 issue of Nature. A small community of researchers continues to investigate it, often under the alternative designations low-energy nuclear reactions (LENR) or condensed matter nuclear science (CMNS).
=== Accolades === Cox's performance in the role has received massive acclaim from critics, having won the Golden Globe Award for Best Actor – Television Series Drama in 2020, as well as a nomination for the same award in 2022, losing to series co-star Jeremy Strong. He has also received nominations for the Primetime Emmy Award for Outstanding Lead Actor in a Drama Series in 2020, 2022, and 2024, the Critics' Choice Television Award for Best Actor in a Drama Series in 2022, the Hollywood Critics Association TV Awards for Best Actor in a Broadcast Network or Cable Series, Drama in 2022, and the Satellite Award for Best Actor – Television Series Drama in 2020 and 2022.
Sources: en.wikipedia.org
TRAFFIC; "New report confirms 'major surge' in ivory smuggling in 2011" EIA "Blood Ivory: Exposing the myth of a regulated market" Federation of Environmental Organizations Sri Lanka: "Blood Ivory to Buddhist Temples?" Gemological properties of ivory The International Ivory Society Maskell, Alfred (1911). "Ivory" . Encyclopædia Britannica. Vol. 15 (11th ed.). pp. 92–98. Includes several diagrams.
== Frequency == Birth defects with symptoms related to CLSD are estimated to affect one in every 500 to 1,000 babies in the United States of America Recommended that CLSD is evaluated in all patients with late-closing fontanels and hypertelorism Recent case found in a caucasian male with a SEC23 inherited mutation from the father combined with another unknown mutation that leads to the symptoms of CLSD despite a healthy gene inherited from the mother Measurement of parental and patient endoplasmic reticulums show distention in both the father and the child, but not the mother as compared to a control measurement. The child was significantly more distended than the father and the mother. Frequency of the disorder may be greater than once thought, and may be linked more closely to all cases of late-closing fontanels and hypertelorism
CmCl3 + 3 NH4I → CmI3 + 3 NH4Cl Or, one can heat curium oxide to ~600 °C with the corresponding acid (such as hydrobromic for curium bromide). Vapor phase hydrolysis of curium(III) chloride gives curium oxychloride:
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.